Filing Details

Accession Number:
0001140361-24-014226
Form Type:
4
Zero Holdings:
No
Publication Time:
2024-03-19 21:48:01
Reporting Period:
2024-03-18
Accepted Time:
2024-03-19 21:48:01
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
1368514 Adma Biologics Inc. ADMA () 4
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1250195 Steve Elms 489 5Th Avenue
10Th Floor
New York NY 10017
No No No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Disposition 2024-03-18 49,887 $6.01 2,527,500 No 4 S Indirect See footnote
Common Stock Disposition 2024-03-19 411,829 $6.08 2,115,671 No 4 S Indirect See footnote
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 S Indirect See footnote
No 4 S Indirect See footnote
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 76,441 Direct
Footnotes
  1. These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10 year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest thereon.
  2. The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.02. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  3. The price shown in Column 4 is a weighted average sale price. The price range for the sales is $6.00 to $6.17. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer or a security holder of the Issuer, full information regarding the number of shares sold at each separate price.
  4. Includes, as of the transaction date, (i) 24,040 restricted stock units ("RSUs") granted on February 26, 2024 and reported on this Form 4, that will vest in two equal installments, on the six- and 12-month anniversaries of the grant date, becoming fully vested on the one-year anniversary of the grant date, subject to the reporting person's continued service as of the applicable vesting date; and (ii) 52,401 shares of common stock owned by the reporting person.